Johnson & Johnson is partnering with Pacira BioSciences for osteoarthritis of the knee, according to a July 22 news release.
The agreement adds Zilretta, an injectable osteoarthritis treatment, to Johnson & Johnson’s portfolio. The companies will also participate in shared professional education and initiatives to increase awareness of nonoperative care.
Zilretta is the first FDA-approved extended-release intra-articular therapy for patients with osteoarthritis-related knee pain. It uses a proprietary microsphere technology combining triamcinolone acetonide with a poly lactic-co-glycolic acid matrix.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
